How commercial trade groups are shifting from distribution execution to strategic partners shaping market access, launch readiness and commercial performance.

Geopolitical instability is pushing life sciences firms to map supply chains beyond suppliers to protect trials and patient access.

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses other standout sessions at this year’s Access Insights conference.

Shawn Seamans, Chief Commercial Officer, CoverMyMeds | Authors | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking ...

EVERSANA's Vikram Anand explains how disconnected PV systems and manual safety processes can create commercial delays after ...

Ten PBMs will integrate TrumpRx cash pricing into RTBT displays, allowing prescribers and patients to compare cash-pay versus plan benefit costs at the point of prescribing. Clinician workflow remains ...

In this week's Pharma Pulse, Trump nominates Heidi Overton to lead the FDA, EVERSANA expands its AI-powered commercialization ...

Cardinal Health's Michelle Britt discusses the operating costs, cash flow strain and reimbursement pressures facing ...

AI in PV can compress the interval between signal observation and documented action, preserving benefit–risk integrity and ...

Trump is expected to pick White House aide Dr. Heidi Overton to lead the FDA, pending Senate confirmation, as the agency works to rebuild industry trust. Overton is among three finalists for the role, ...

Anamika Krishanpal, PhD, is a life sciences digital leader with over 15 years of experience operating at the intersection of biological domain science and digital engineering.